Gold prices suffered their worst single-session decline in a year on Monday to settle below $1,400 an ounce, after a weekend Sino-American trade accord sparked a rally in assets perceived as risky, luring investors away from so-called havens like bullion.
Resolution to China trade tensions could boost Apple’s stock price by $20 to $25 in coming months, per analyst
U.S. financial markets will be closed in observance of Independence Day but back to normal hours on Friday
‘Market expectations from a valuation perspective have gotten ahead of themselves’
CarMax, Inc (NYSE:KMX) – Stock analysts at Oppenheimer raised their Q1 2020 EPS estimates for shares of CarMax in a research report issued on Friday, June 14th, Zacks Investment Research reports. Oppenheimer analyst B. Nagel now expects that the company will post earnings per share of $1.50 for the quarter, up from their previous estimate of $1.45. Oppenheimer has a “Outperform” rating and a $100.00 price objective on the stock. Oppenheimer also issued estimates for CarMax’s Q3 2020 earnings at $1.14 EPS, Q4 2020 earnings at $1.21 EPS, FY2020 earnings at $5.17 EPS and FY2021 earnings at $5.60 EPS.
UniFirst Corp (NYSE:UNF) – Research analysts at Northcoast Research boosted their FY2019 EPS estimates for shares of UniFirst in a research note issued on Thursday, June 27th. Northcoast Research analyst J. Healy now anticipates that the textile maker will post earnings per share of $7.77 for the year, up from their prior estimate of $6.93.
Umpqua Holdings Corp (NASDAQ:UMPQ) – Equities researchers at SunTrust Banks upped their Q3 2019 EPS estimates for Umpqua in a research note issued to investors on Thursday, June 27th. SunTrust Banks analyst M. Young now forecasts that the bank will earn $0.41 per share for the quarter, up from their prior estimate of $0.40.
Infinity Pharmaceuticals Inc. (NASDAQ:INFI) – Oppenheimer issued their Q2 2019 earnings estimates for Infinity Pharmaceuticals in a note issued to investors on Wednesday, June 26th. Oppenheimer analyst K. Degeeter anticipates that the biotechnology company will post earnings of ($0.15) per share for the quarter. Oppenheimer has a “Outperform” rating and a $3.00 price target on the stock. Oppenheimer also issued estimates for Infinity Pharmaceuticals’ Q3 2019 earnings at ($0.16) EPS, Q4 2019 earnings at ($0.18) EPS, FY2019 earnings at ($0.73) EPS, FY2020 earnings at ($0.77) EPS and FY2021 earnings at ($0.91) EPS.
Japan has defended a decision to slap restrictions on exports of certain high-tech materials to South Korea, citing national security concerns.
Efforts by world powers to preserve a 2015 landmark nuclear deal with Iran grew more complicated Monday with confirmation that Tehran had breached the pact’s limitations on stockpiles of low-enriched uranium.
New bowel cancer target could help chill disease aggression and spread
FDA emphasizes available information in final CAR-T guidance while acknowledging lack of precedent
Clarius tacks on European nod for whole-body hand-held ultrasound scanner
Elicio’s therapeutic cancer vaccine boosts T-cell therapy response in mice while biotech awaits phase 2 data
Sarepta’s next DMD drug seems to get the job done, but Elevidys casts long shadow
After GSK and Novartis handoffs, Laekna’s drug fails ovarian cancer trial
Ascendis spins out new ophthalmology biotech Eyconis, gaining equity and biobucks
Next-gen prostate cancer test maker Cleveland Diagnostics rocks to $75M fundraising
Philips agrees to FDA consent decree halting US sales of CPAP respiratory care devices
Samsung taps Lunit to bring AI detection to its chest X-ray scanners
